Lv41
490 积分 2023-07-11 加入
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma
1小时前
待确认
Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma
1小时前
待确认
Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma
1小时前
已关闭
Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma
1小时前
已关闭
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy
2个月前
已完结
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
2个月前
已完结
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
2个月前
已关闭
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
2个月前
已关闭
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
2个月前
已关闭
KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma
2个月前
已完结
皖公网安备34019202002308
